MIFF 发表于 2025-3-21 20:07:59
书目名称Cancer Immunotherapies影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0221136<br><br> <br><br>书目名称Cancer Immunotherapies读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0221136<br><br> <br><br>lobster 发表于 2025-3-21 21:18:16
http://reply.papertrans.cn/23/2212/221136/221136_2.pngEVADE 发表于 2025-3-22 03:22:36
http://reply.papertrans.cn/23/2212/221136/221136_3.png死亡 发表于 2025-3-22 07:15:22
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma,efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers. Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.懒洋洋 发表于 2025-3-22 10:11:33
http://reply.papertrans.cn/23/2212/221136/221136_5.png知识分子 发表于 2025-3-22 14:14:34
http://reply.papertrans.cn/23/2212/221136/221136_6.png知识分子 发表于 2025-3-22 19:48:02
http://reply.papertrans.cn/23/2212/221136/221136_7.png过多 发表于 2025-3-22 22:46:33
http://reply.papertrans.cn/23/2212/221136/221136_8.pngCompassionate 发表于 2025-3-23 03:57:47
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity,rticularly with the goal of generating Th1-promoting inflammation that stokes endogenous priming of antitumor CD8. T cells, is a growing area of clinical investigation. This approach is analogous to in situ vaccination, ultimately providing a personalized antitumor response against relevant tumor asExuberance 发表于 2025-3-23 05:47:12
http://reply.papertrans.cn/23/2212/221136/221136_10.png